Brief: Auransa Enters Exclusive Licensing Agreement With China Oncology Focus Limited

Lees Pharmaceutical Holdings

19/12/2018 12:29

Dec 19 (Reuters) - Lee's Pharmaceutical Holdings Ltd
 0950.HK :
    * AURANSA ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH
CHINA
ONCOLOGY FOCUS LIMITED, AN AFFILIATE OF LEE’S PHARMACEUTICAL
HOLDINGS, FOR RIGHTS TO AU018 IN GREATER CHINA AND SOUTHEAST
ASIA
    * AURANSA ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH
CHINA
ONCOLOGY FOCUS LIMITED, AN AFFILIATE OF LEE’S PHARMACEUTICAL
HOLDINGS, FOR RIGHTS TO AU018 IN GREATER CHINA AND SOUTHEAST
ASIA
    * AURANSA - AURANSA IS ELIGIBLE TO RECEIVE UP TO $22.5
MILLION
UPON SUCCESSFUL ATTAINMENT OF KEY MILESTONES
    * AURANSA - WILL RECEIVE AN UPFRONT PAYMENT, POTENTIAL
FUTURE
MILESTONE PAYMENTS AND HIGH SINGLE DIGIT ROYALTIES ON FUTURE NET
SALES
    * AURANSA - COF WILL BE RESPONSIBLE FOR FUNDING AND
CONDUCTING ALL
REMAINING PRECLINICAL AND CLINICAL ACTIVITIES
    * AURANSA - COMPANY WILL RETAIN RIGHTS TO AU018 FOR ALL
MARKETS
OUTSIDE SCOPE OF THIS AGREEMENT
    * AURANSA - WILL HAVE RIGHTS TO ACCESS AND USE ANY AU018
DATA
GENERATED BY COF AS PART OF ITS DEVELOPMENT AND
COMMERCIALIZATION EFFORTS

Source text for Eikon:  ID:nGNXbmtRsN 
Further company coverage:  0950.HK 

 ((Reuters.Briefs@thomsonreuters.com;))